Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth
|
|
- Donna Dixon
- 8 years ago
- Views:
Transcription
1 Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth 1
2 About EFPIA Þ EFPIA is the voice of the European innovative pharmaceutical industry, representing the world s leading research-based pharmaceutical companies Þ The pharmaceutical industry directly employs over people in Europe, including in research and innovation, as well as creating four times as many jobs downstream Þ The pharmaceutical industry is one of the key assets of the EU economy, creating employment and investing in medical progress through research and development - bringing new and innovative medicines that improve the health and quality of life for patients all over Europe, and the world 2
3 Outline Þ TTIP: a unique opportunity for our industry and for patients Þ Main TTIP objectives bringing benefits to both industry and patients Þ Regulatory Convergence Þ Intellectual Property Protection and Enforcement Þ Market Access 3
4 Strong support for an ambitious TTIP - bringing benefits to patients, science and the economy (I) Þ TTIP can serve as a key platform to foster benefits for the broader life sciences sector, but also has the potential to facilitate the development of new medicines and improve health outcomes. Quicker and more efficient regulatory processes could benefit patients by resulting in faster access to new medicines Þ We support an ambitious and comprehensive agreement that addresses regulatory compatibility initiatives, intellectual property protection and provides for greater market access, which also contains strong commitments for increased investment protection, elimination of all tariffs and streamlined rules of origin 4
5 Strong support for an ambitious TTIP - bringing benefits to patients, science and the economy (II) Þ Aware of the challenges - longstanding process of bridging gaps Þ 20 months after launch of negotiations, slow but steady progress has been made with technical discussions underway. Þ Need to realise the significant potential of TTIP to strengthen the competitiveness of European industry, providing jobs, economic growth, innovation opportunities and faster new medicines to patients Þ Political will needed to deliver an ambitious agenda Þ Continued support from 28 EU Member States is essential Þ Strengthened engagement with European Parliament Þ Increased dialogue with civil society 5
6 The value of our Industry 6
7 EU US pharmaceutical marketplace Þ Transatlantic pharmaceutical marketplace: EU and US represent the two largest markets for pharmaceuticals. Þ EU and US together attract more than 75% of global investment in life-science research. Þ It is the combined home for 9 out of the top 10 worldwide pharmaceutical companies. Geographical breakdown (by main markets) of sales of new medicines launched during the period % Pharmerging 55 % US 23 % Europe 10% Japan 9 % ROW Source: IMS Health MIDAS April
8 EU bilateral trade with the US EU Exports EU Imports USA Switzerland USA Switzerland Russia Japan Singapore China China Others Israel Others 44% 27% 4% 13% 4% 6% 37% 10% 5% 7% 7% 36% The US is the largest market both for EU exports and imports Source: Eurostat COMEXT database April
9 Great potential for strengthening the pharmaceutical market Large companies and SMEs all benefit from greater opportunities: ü Increased bilateral trade ü Predictable investment climate ü Closer research cooperation Resulting in: Ø Enhanced efficiency of drug development Ø Expedited patient access to new, innovative medicines. 9
10 Regulatory convergence (I) Þ TTIP is a unique opportunity to seek greater regulatory convergence and to create streamlined processes and procedures between the EU and the US Þ The ultimate goal should be to facilitate R&D investment in new and innovative medicines, targeting the unmet needs of patients around the globe Þ TTIP provides a powerful platform to address remaining divergences, in a more expeditious manner, building on longstanding cooperation between the two parties Þ Regulatory convergence can result in: Þ Elimination of unnecessary duplicative submissions, evaluations testing and inspections Þ Harmonisation of processes, which can speed up patients access to medicines Þ Optimising deployment of resources in regulatory agencies and reducing red tape for companies Þ Stimulation of the development and competitiveness of the industry, while ensuring the maintenance of high standards for the quality, safety and efficacy of medicines 10
11 Regulatory convergence (II) Our proposals: Þ Mutual recognition of GMP (Good Manufacturing Practice) inspections Þ Potential to reduce inspections by 40%, generating significant savings for industry and regulators, allowing agencies to focus on higher risk areas Þ Streamlining of the content and timing of submission of harmonised paediatric plans Þ Establishment of a harmonised list of clinical trial results data fields Þ Establishment of a harmonised approach to post-approval variation submissions for CMC (chemistry, manufacturing and control) changes Ø Need for a built-in agenda allowing for progressive greater regulatory convergence over time in order to address joint approaches to compatibility processes as science evolves 11
12 Intellectual Property Rights (I) Þ Both the EU and US recognize the value of IP as the lifeblood of innovative industries and provide for strong protection of IPRs within their respective systems Þ TTIP is a great opportunity for the inclusion of a commitment to shared principles Þ To ensure future competitiveness, both systems should be open to further adaptation in order to incentivise research into unmet needs 12
13 Intellectual Property Rights (II) Our proposals Þ Joint commitment to existing high-level standards for IP protection and enforcement and the establishment of joint IP principles that the EU and the US should treat as a point of reference in all future bilateral and multilateral trade agreements Þ Joint commitment to support enhanced cooperation between patent offices, working towards substantive patent law harmonisation, including a grace period Þ Provide for effective patent enforcement opportunities and support the introduction of an Early Resolution Mechanism 13
14 Market Access Þ TTIP should ensure that government policies for pricing and reimbursement processes do not create obstacles to pharmaceutical trade between the two parties. Þ Need to negotiate a Pharmaceutical Annex on government pricing and reimbursement policies that Þ Promotes transparency principles in processes Þ Adequately recognises the value of pharmaceuticals and rewards innovation Þ In line with the EU Transparency Directive (Directive 89/105/EEC) Þ Building on recently agreed EU FTAs, i.e. EU-Korea FTA Þ Also covered by U.S.-Korea FTA 14
15 TTIP can benefit patients, science and the economy Increasing the efficiency of approving new medicines results in patients getting faster access to new treatments Mutual recognition of manufacturing site inspections can optimise regulators resources and reduce costs Reducing the number of clinical trials involving children Increasing regulatory convergence can stimulate SMEs and the life sciences ecosystem Encouraging the development of new medicines and vaccines, and strengthening research cooperation Increasing transparency and due process in pricing and reimbursement systems Sustaining the creation of jobs in the pharmaceutical sector 15
16 Thank you! EFPIA Brussels Office Leopold Plaza Building Rue du Trône 108 B-1050 Brussels - Belgium Tel: +32 (0) EFPIA TTIP Brochure
»Market Access Database
The European Union Trade and Investment Policy»Market Access Database Filip Deraedt European Commission Trade» Free Trade Agreements Trade Policy Agenda Trade, Growth and World Affairs Foster open markets
More informationThe Transatlantic Trade and Investment Partnership (TTIP) State of Play
The Transatlantic Trade and Investment Partnership (TTIP) State of Play 27 April 2016 27 April 2016 Background / context for the negotiations The European Union and the United States have the most integrated
More informationFinal Report High Level Working Group on Jobs and Growth
Final Report High Level Working Group on Jobs and Growth February 11, 2013 INTRODUCTION As the United States-European Union High Level Working Group on Jobs and Growth (HLWG) noted in its June 19, 2012
More informationMay 10, 2013. Office of the United States Trade Representative 600 17 th Street NW Washington, D.C. 20508
Office of the United States Trade Representative 600 17 th Street NW Washington, D.C. 20508 May 10, 2013 Submitted electronically via www.regulations.gov Attn: Docket: USTR-2013-0019 Re: Trans-Atlantic
More informationInternational cooperation
International cooperation KIPO-WIPO cooperation Bilateral and trilateral cooperation International IPR discussions IPR issues and free trade agreements International cooperation KIPO-WIPO cooperation A
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationFRAMEWORK FOR ADVANCING TRANSATLANTIC ECONOMIC INTEGRATION BETWEEN THE EUROPEAN UNION AND THE UNITED STATES OF AMERICA
FRAMEWORK FOR ADVANCING TRANSATLANTIC ECONOMIC INTEGRATION BETWEEN THE EUROPEAN UNION AND THE UNITED STATES OF AMERICA We, leaders of the European Union and the United States of America: Believing that
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 18.4.2007 COM(2007) 183 final COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND
More informationPROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE
PROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE Joint study by the WHO, WIPO and WTO Secretariats Outline and overview The WHO, WIPO and the
More informationThe EFPIA Disclosure Code: Your Questions Answered
The EFPIA Disclosure Code: Your Questions Answered Working together: why do the pharmaceutical industry and healthcare professionals work together? 1 Why does industry pay health professionals to provide
More informationClinical Trial Transparency. What is available?
Clinical Trial Transparency What is available? 1 Outline Clinical Trial Data Collection and Reporting Data Definitions Clinical Trial Transparency Summary Report Requirements Example of Results Posting
More informationGerman Insurance Association
German Insurance Association Key regulatory and market access issues in relations with specific third countries ID-Number 6437280268-55 Gesamtverband der Deutschen Versicherungswirtschaft e. V. German
More informationEFPIA Good Practice Revision 1, October 2014
EFPIA Good Practice Revision 1, October 2014 Reducing Risk of Drug Products Shortages Introduction Authorities, industry and healthcare providers have a responsibility to ensure a modern and sustainable
More informationEFPIA position on Clinical Trials Regulation trialogue
EFPIA position on Clinical Trials Regulation trialogue As the revision of the Clinical Trial Directive enters the Trialogue phase, it is critical to remember that the key objective of this legislation
More informationTaking a Leap Toward Global Supply Chain Efficiency
Taking a Leap Toward Global Supply Chain Efficiency 2 Taking a Leap Toward Global Supply Chain Efficiency INTRODUCTION PROBLEM STATEMENT Pharmaceutical manufacturers face a number of challenges to produce
More informationTransatlantic Trade and Investment Partnership. The Regulatory Part
Transatlantic Trade and Investment Partnership The Regulatory Part September 2013 2 Presidents Barroso, Van Rompuy and Obama have made clear that reducing regulatory barriers to trade will be one of the
More informationProvisions in TTIP should not interfere with voluntary and business-driven approaches by companies such as corporate social responsibility (CSR).
POSITION PAPER May 2015 TTIP: the sustainability chapter KEY MESSAGES 1 pr in ci 2 pl e 3 p ur 4 p o 5 s e a n d fu n ct io The main objective of TTIP is to boost trade and investments between the European
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationEDRi s. January 2015. European Digital Rights Rue Belliard 20, 1040 Brussels www.edri.org @EDRi tel. +32 (0) 2 274 25 70
EDRi s Red lines on TTIP January 2015 European Digital Rights Rue Belliard 20, 1040 Brussels www.edri.org @EDRi tel. +32 (0) 2 274 25 70 ABOUT EDRI European Digital Rights is a network of 34 privacy and
More informationThe first round of TPP negotiations was held in Melbourne in March 2010.
AN INTRODUCTION History The Trans-Pacific Partnership (TPP) builds from the Trans-Pacific Strategic Economic Partnership Agreement (P4) between Brunei, Chile, New Zealand and Singapore which entered into
More informationCLINICAL TRIALS WITH MEDICINES IN EUROPE
CLINICAL TRIALS WITH MEDICINES IN EUROPE REGULATORY FRAMEWORK FOR CLINICAL TRIALS WITH MEDICINES IN EUROPE The pharmaceutical industry is the most highly regulated sector in Europe. The Commission has
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationThe new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
More informationUPDATE ON THE TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP (TTIP) - FIRST NEGOTIATION ROUND
CIVIL SOCIETY DIALOGUE UPDATE ON THE TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP (TTIP) - FIRST NEGOTIATION ROUND Date: 16/07/2013 Time: 14:30 16:30 Location: Charlemagne Building, room Alcide de Gasperi,
More information* * * Initial Provisions for. CHAPTER [ ] - Regulatory Cooperation
REMARKS: This is an initial textual proposal for a draft Chapter on Regulatory Cooperation that the Commission intends to submit to the US on Friday, 30 January, in preparation of the 8 th round of TTIP
More information(Article 131(2) of the Financial Rules of the Innovative Medicines Initiative Joint Undertaking)
Annual report of the Executive Director to the Discharge on measures taken in the light of the Discharge s recommendations of 2012 in respect of the implementation of the budget of 2010 (Article 131(2)
More informationMr Roger Marshall Acting President EFRAG Board European Financial Reporting Advisory Group (EFRAG) 35 Square de Meeüs 1000 Brussels Belgium
* esma European Securities and Markel:s Authority *** The Chair 19 November2015 ESMA/2015/1739 Mr Roger Marshall Acting President EFRAG Board European Financial Reporting Advisory Group (EFRAG) 35 Square
More informationJoint statement on supply-chain security
Joint statement on supply-chain security The United States and the European Union face similar challenges and share a common approach to the security ofthe supply-chain. We have witnessed several incidents,
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
More informationAmCham EU s position on the Transatlantic Trade and Investment Partnership (TTIP)
AmCham EU s position on the Transatlantic Trade and Investment Partnership (TTIP) Building the framework for strengthening the transatlantic partnership 14 March 2014 Executive summary The American Chamber
More informationBACKGROUND 1 FOREIGN AFFAIRS COUNCIL - TRADE ISSUES Thursday 8 May in Brussels
Brussels, 5 May 2014 BACKGROUND 1 FOREIGN AFFAIRS COUNCIL - TRADE ISSUES Thursday 8 May in Brussels The Council will take note of progress on the remaining technical issues to be resolved on a comprehensive
More informationGerman Industry's Priorities for a Transatlantic Trade and Investment Partnership (TTIP)
German Industry's Priorities for a Transatlantic Trade and Investment Partnership (TTIP) Executive Summary German Industry welcomes the launch of negotiations for a comprehensive and ambitious transatlantic
More informationDG Trade September 2013
DG Trade September 2013 Trade negotiations step by step Content: 1. Who negotiates? 2. Who do we negotiate with? 3. How do we prepare for negotiations? 4. What happens in negotiations? 5. Conclusion of
More informationBIO-PARTNERING EUROPE EVENT SPEECH PAOLA TESTORI COGGI DIRECTOR GENERAL FOR HEALTH AND CONSUMERS EUROPEAN COMMISSION
EUROPABIO BIO-PARTNERING EUROPE EVENT TUESDAY 9 OCTOBER 2012 9.10 9.20 HRS SPEECH BY PAOLA TESTORI COGGI DIRECTOR GENERAL FOR HEALTH AND CONSUMERS EUROPEAN COMMISSION I am pleased to have the opportunity
More informationOkinawa Charter on Global Information Society
Okinawa Charter on Global Information Society 1. Information and Communications Technology (IT) is one of the most potent forces in shaping the twenty-first century. Its revolutionary impact affects the
More informationOutlines of the Trans-Pacific Partnership Agreement
Page 1 of 5 Outlines of the Trans-Pacific Partnership Agreement ENHANCING TRADE AND INVESTMENT, SUPPORTING JOBS, ECONOMIC GROWTH AND DEVELOPMENT: OUTLINES OF THE TRANS-PACIFIC PARTNERSHIP AGREEMENT On
More informationIPROVE Innovation Partnership for a Roadmapon VaccinesinEurope
IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope IPROVE IN BRIEF What is IPROVE? Whydo we need IPROVE? IPROVE in actions (How?) Partnership (Who?) WHAT An EU project (FP7) financed by the
More informationFinal Resolution for the 6 th European Interparliamentary Space Conference (EISC), held on November 10 th and 11 th 2004
Final Resolution for the 6 th European Interparliamentary Space Conference (EISC), held on November 10 th and 11 th 2004 The 6 th European Interparliamentary Space Conference (EISC), held at the Congress
More informationIntroduction to Q10 Pharmaceutical Quality System
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
More informationRE: Transatlantic Business Concerns about Indian Government IP Policies
The Honorable Michael Froman Assistant to the President and Deputy National Security Adviser for International Economic Affairs The White House Washington, DC 20504 USA Ambassador Ron Kirk U.S. Trade Representative
More informationSUPPLY CHAIN SECURITY: THE CUSTOMS COMMUNITY S RESPONSE
World Customs Journal SUPPLY CHAIN SECURITY: THE CUSTOMS COMMUNITY S RESPONSE Abstract Kunio Mikuriya The international customs community has developed measures to secure and facilitate global trade which
More informationTrade for all. Towards a more responsible trade and investment policy. Trade
Trade for all Towards a more responsible trade and investment policy Trade Europe Direct is a service to help you find answers to your questions about the European Union. Freephone number (*): 00 800 6
More informationTEXTUAL PROPOSAL TECHNICAL BARRIERS TO TRADE (TBT) Article 1 Objective and Scope
TEXTUAL PROPOSAL TECHNICAL BARRIERS TO TRADE (TBT) Article 1 Objective and Scope 1. The objective of this Chapter is to promote convergence in regulatory approaches, by reducing or eliminating conflicting
More informationANALYSIS OF THE STAKEHOLDER CONSULTATION ON
ANALYSIS OF THE STAKEHOLDER CONSULTATION ON Science and Technology, the key to Europe s future: guidelines for future European policy to support research COM(353)2004 DG Research, European Commission,
More informationConsumers at the heart of the Transatlantic Trade and Investment Partnership (TTIP)
Consumers at the heart of the Transatlantic Trade and Investment Partnership (TTIP) BEUC Position Statement 1 Contact: Monique Goyens directorsoffice@beuc.eu Ref.: BEUC-X-2014-031 - 06/05/2014 1 Last update
More informationInitial Provisions for CHAPTER [ ] Regulatory Cooperation
Initial Provisions for CHAPTER [ ] Regulatory Cooperation General notes: 1. As TTIP negotiations progress, the provisions in this Chapter may be reviewed in the light of developments in other Chapters,
More informationCouncil conclusions on strengthening the external dimension of the EU energy policy
COUNCIL OF THE EUROPEAN UNION Council conclusions on strengthening the external dimension of the EU energy policy 3127th TRANSPORT, TELECOMMUNICATIONS and ERGY Council meeting (Energy items) Brussels,
More informationWork plan for GMP/GDP Inspectors Working Group for 2016
21 December 2015 EMA/INS/GMP/738756/2015 Compliance and Inspection Work plan for GMP/GDP Inspectors Working Group for 2016 Chairperson: Status David Cockburn January 2016 1. Meetings scheduled for 2016
More informationThe Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
More informationQualitative analysis of a potential Free Trade Agreement between the European Union and India. Executive Summary
Centre for the Analysis of Regional Integration at Sussex Qualitative analysis of a potential Free Trade Agreement between the European Union and India Executive Summary Centre for the Analysis of Regional
More informationThe Danish pharmaceutical industry and TTIP
The Danish pharmaceutical Leo Novo Pharma Nordisk A/S Lundbeck Lundbeck - Novo A/S Nordisk - LEO Pharma A/S CONTENT 1. Summary and introduction 2. The importance of pharma in the Danish economy 3. Benefits
More informationClinical trials in developing countries submitted to EMEA for regulatory purposes
Clinical trials in developing countries submitted to EMEA for regulatory purposes Rome, UNICRI/AIFA December 2008 Hans-Georg Eichler Agenda Challenges EU regulatory requirements for clinical trials Facts
More informationCouncil of the European Union Brussels, 9 October 2014 (OR. en)
Council of the European Union Brussels, 9 October 2014 (OR. en) 11103/13 DCL 1 DECLASSIFICATION of document: dated: 17 June 2013 new status: Subject: WTO 139 SERVICES 26 FDI 17 USA 18 ST 11103/13 RESTREINT
More informationJanuary 2015. Eurogas Views on the Energy Union and Enhancing Supply Security
January 2015 Eurogas Views on the Energy Union and Enhancing Supply Security Eurogas is the association representing the European gas wholesale, retail and distribution sectors. Founded in 1990, its members
More informationCOMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
EUROPEAN COMMISSION Strasbourg, 12.12.2012 COM(2012) 746 final COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF
More informationChains. T-TIP Stakeholder Presentation 5 th Round Arlington, VA May 21, 2014
Risk Management and Global Supply Chains T-TIP Stakeholder Presentation 5 th Round Arlington, VA May 21, 2014 AAEI Works with European Partners What Are the General Trends for Trade? Compliance Facilitation
More informationICH Q10 Pharmaceutical Quality System (PQS)
ICH Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Q10 PQS Guideline Background Objectives
More informationEU-China Summit joint statement. The way forward after forty years of EU-China cooperation
29 June, 2015 EU-China Summit joint statement The way forward after forty years of EU-China cooperation 1. Mr. Donald Tusk, President of the European Council, Mr. Jean-Claude Juncker, President of the
More informationExecutive Summary, 21 January 2015
January 2015 Study by the Ifo Institute, Munich, and the Institute for Applied Economic Research (IAW), Tübingen commissioned by the German Federal Ministry for Economic Cooperation and Development (BMZ)
More informationOPEN MARKETS FOR INTERNATIONAL TRADE AND INVESTMENT
OPEN MARKETS FOR INTERNATIONAL TRADE AND INVESTMENT Fast Facts In 2008, more than 38 million jobs in America more than one in five depended on international trade exports and imports. 1 In 1992, a year
More informationCEEP OPINION ON THE TRANSATLANTIC TRADE
Brussels, 12 June 2014 Opinion.05 CEEP OPINION ON THE TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP (TTIP) Executive Summary Focus 1: The respect of the EU Treaty Principle and EU political balance on
More informationPublic consultation on the future of EU-US trade and economic relations
Public consultation on the future of EU-US trade and economic relations Introduction The US is a strategic partner of the EU. Both the EU and the US are strong promoters of free trade and investment and
More informationEU initiative on the Access to the EU Public Procurement markets
EU initiative on the Access to the EU Public Procurement markets A Tool to Regain Leverage Anders C. Jessen Head of Unit, Public Procurement and Intellectual Property, DG Trade, European Commission Content
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationFIDIC Capacity Building. A Major Role for FIDIC in the Consulting Engineering Industry
FIDIC Capacity Building A Major Role for FIDIC in the Consulting Engineering Industry FIDIC Capacity Building A Major Role for FIDIC in the Consulting Engineering Industry FIDIC Capacity Building The
More informationTACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES
TRANSATLANTIC CONSUMER DIALOGUE WASHINGTON MEETING, 10-12 FEBRUARY 2000 TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES The Commission Services
More informationEUROPEAN UNIVERSITIES CHARTER ON LIFELONG LEARNING
EUROPEAN UNIVERSITIES CHARTER ON LIFELONG LEARNING Copyright 2008 by the European University Association All rights reserved. This information may be freely used and copied for non-commercial purposes,
More informationGLOBAL EUROPE. competing in the world. A Contribution. to the EU s Growth. and Jobs Strategy. External Trade. European Commission
GLOBAL EUROPE competing in the world A Contribution to the EU s Growth and Jobs Strategy European Commission External Trade 1 Purpose 2 of the Communication Growth and jobs, and the opportunity they create,
More information10721/16 GSC/lt 1 DGB 2B
Council of the European Union Brussels, 28 June 2016 (OR. en) 10721/16 OUTCOME OF PROCEEDINGS From: General Secretariat of the Council On: 28 June 2016 To: Delegations No. prev. doc.: 10320/16 REV 1 Subject:
More informationCOMMISSION STAFF WORKING DOCUMENT. Report on the Implementation of the Communication 'Unleashing the Potential of Cloud Computing in Europe'
EUROPEAN COMMISSION Brussels, 2.7.2014 SWD(2014) 214 final COMMISSION STAFF WORKING DOCUMENT Report on the Implementation of the Communication 'Unleashing the Potential of Cloud Computing in Europe' Accompanying
More informationHarmonisation of electricity generation transmission tariffs. A EURELECTRIC contribution to ACER s scoping exercise
Harmonisation of electricity generation transmission tariffs A EURELECTRIC contribution to ACER s scoping exercise December 2015 EURELECTRIC is the voice of the electricity industry in Europe. We speak
More informationHow To Understand The Paediatric Regulation
Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative
More informationPromoting Cross Border Data Flows Priorities for the Business Community
Promoting Cross Border Data Flows Priorities for the Business Community The movement of electronic information across borders is critical to businesses around the world, but the international rules governing
More informationPresentation by Mr. Richard Bruton, Minister of Jobs, Enterprise and Innovation to the IMCO Committee of the European Parliament, Brussels
Presentation by Mr. Richard Bruton, Minister of Jobs, Enterprise and Innovation to the IMCO Committee of the European Parliament, Brussels Wednesday 23 rd January 2013 Check against delivery Honourable
More informationFinal Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed by the ICH SC on 10 November 2005
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Final Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed
More informationSpurring Growth of Renewable Energies in MENA through Private Sector Investment
MENA-OECD Business Council: Task Force on Energy and Infrastructure WORKING PAPER PRESENTING THE PRIVATE SECTOR S VIEW Spurring Growth of Renewable Energies in MENA through Private Sector Investment Agenda
More informationTrade Debates - Liberal Voices Needed
European Commission Speech [Check against delivery] Trade Debates - Liberal Voices Needed 3 December 2015 Cecilia Malmström, Commissioner for Trade Berlin Event at Friedrich Naumann Stiftung Ladies and
More informationOverview of the EHR4CR project Electronic Health Record systems for Clinical Research
Overview of the EHR4CR project Electronic Health Record systems for Clinical Research Dipak Kalra UCL on behalf of the EHR4CR Consortium ENCePP Plenary Meeting, 3rd May 2012, London The problem (as addressed
More informationTentative Action Plan
Republic of Serbia Ministry of Science and Environmental Protection Serbia and Montenegro Tentative Action Plan Draft 1 Belgrade, September 2005 Tentative Action Plan - Draft 1 Section 1 and 2 Information
More informationF A C T S H E E T. EU-US Summit (Brussels, 26 March 2014) and EU-US relations
Brussels, 24 March 2014 140324/01 F A C T S H E E T EU-US Summit (Brussels, 26 March 2014) and EU-US relations The Leaders of the European Union and the United States of America will meet on 26 March 2014
More informationRealising the European Higher Education Area - Achieving the Goals. Conference of European Higher Education Ministers
EUROPEAN COMMISSION Education and Culture Realising the European Higher Education Area - Achieving the Goals Conference of European Higher Education Ministers Contribution of the European Commission Bergen,
More informationI. What is the DCFTA?
DEEP AND COMPREHENSIVE FREE TRADE AREA EU-MOLDOVA I. What is the DCFTA? Argumentaire The Deep and Comprehensive Free Trade Area (DCFTA) is an arrangement between the EU and the Republic of Moldova that
More informationContext and Objective
Edna dos Santos-Duisenberg (edna.dos.santos@unctad.org) Chief, Creative Economy Programme Euro-African Campus for Cultural Cooperation, Maputo, June 2009 1 Context and Objective First UN multi-agency report
More informationThe Bordeaux Communiqué
The Bordeaux Communiqué on enhanced European cooperation in vocational education and training Communiqué of the European Ministers for vocational education and training, the European social partners and
More informationAchievements and challenges of the single market. S&D responses to citizens top 10 concerns
Achievements and challenges of the single market S&D responses to citizens top 10 concerns The European economic model must be based on three principles: competition which stimulates, co-operation which
More informationSANITARY AND PHYTOSANITARY MEASURES (SPS)
TEXTUAL PROPOSAL SANITARY AND PHYTOSANITARY MEASURES (SPS) Article 1 Scope and coverage This Chapter applies to all SPS measures that may, directly or indirectly, affect trade between the Parties. This
More informationMemorandum of Understanding on Labour Cooperation
Memorandum of Understanding on Labour Cooperation The Department of Labour of New Zealand, in the name of New Zealand and the Ministry of Human Resources and Social Security of the People s Republic of
More informationStudy on the regulation of Voice over IP (including numbering aspects) in Europe
Study on the regulation of Voice over IP (including numbering aspects) in Europe Dieter Elixmann J. Scott Marcus Dr. Christian Wernick Presentation of Results Brussels, March 11, 2008 0 Introduction Agenda
More informationCOMPROMISE AMENDMENTS
COMPROMISE AMENDMENTS on draft report containing the European Parliament's recommendations to the Commission on the negotiations for TTIP 2014/2228(INI) CAM 1 Rapporteur: Bernd LANGE 1. CITATIONS AND RECITALS
More informationThe New Transatlantic Agenda
The New Transatlantic Agenda 1. Promoting Peace And Stability, Democracy And Development Around The World 2. Responding To Global Challenges 3. Contributing To The Expansion Of World Trade And Closer Economic
More informationA Trade Agenda that Gets Results
A Trade Agenda that Gets Results Annex to the Canadian Chamber of Commerce Election Platform June 2015 A Trade Agenda that Gets Results The Canadian Chamber of Commerce 1 Canada s next government should
More informationFederal agency for medicines and health products
Federal agency for medicines and health products A critical review of the proposed EU Clinical Trial regulation Walter Janssens Kristof Bonnarens April 2013 CT regulation - general Commission adopted the
More informationPublic Private Partnership as Industrial Research and Innovation Instruments The way forward
Spanish non paper Public Private Partnership as Industrial Research and Innovation Instruments The way forward The purpose of this document is to capture the view of the Spanish Presidency of the European
More informationQuestions and Answers on the European Commission Communication: The Paris Protocol A blueprint for tackling global climate change beyond 2020
European Commission - Fact Sheet Questions and Answers on the European Commission Communication: The Paris Protocol A blueprint for tackling global climate change beyond 2020 Brussels, 25 February 2015
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013) IMPORTATION OF ACTIVE SUBSTANCES
More informationNovember 03, 2009. Via Electronic Mail to www.regulations.gov
November 03, 2009 Via Electronic Mail to www.regulations.gov Ms. Gloria Blue Executive Secretary, Trade Policy Staff Committee Office of the U.S. Trade Representative 600 17th Street, N.W. Washington,
More informationDIGITALEUROPE and European Services Forum (ESF) response to the Draft Supervision Rules on Insurance Institutions Adopting Digitalised Operations
DIGITALEUROPE and European Services Forum (ESF) response to the Draft Supervision Rules on Insurance Institutions Adopting Digitalised Operations Brussels, October 2015 INTRODUCTION On behalf of the European
More informationForest Law Enforcement Governance and Trade (FLEGT) Voluntary Partnership Agreements (VPAs) or How to do effective consultation for national policies?
Forest Law Enforcement Governance and Trade (FLEGT) Voluntary Partnership Agreements (VPAs) or How to do effective consultation for national policies? Kerstin Canby Forest Trends May 2013 Which Which FLEGT
More informationGEOPOLITICS OF ENERGY AND ENERGY SECURITY A EUROPEAN PERSPECTIVE
GEOPOLITICS OF ENERGY AND ENERGY SECURITY A EUROPEAN PERSPECTIVE Jean-Paul Decaestecker Council of the European Union Energy Foresight Symposium 2007 BERGEN, 22-23 March 2007 EFS 2007 The views expressed
More information